MDM2 and breast carcinoma: Taken together, these studies emphasize a mechanism for the anti-tumor activity observed for pharmacological MDM2 inhibition in TNBC independent of p53 function and stresses its therapeutic potential in this breast cancer subtype in the presence of inactivating p53 mutations.